Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]DPA-714 PET Imaging in Cognitive Decline
NCT02062099Phase 1Completed
- Sponsor
- University Hospital Tours
- Start
- Jan 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DPA-714 in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by University Hospital Tours. Primary endpoints: Binding Potential of [18F]DPA-714 at 2 years and Standard Uptake Values ratio of [18F]AV-45 at 2 years. Started Jan 2014; status: completed.
02
Drugs
DPA-714
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02062099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062099.